https://apnews.com/press-release/business-wire/kallyopes-phase-2b-study-of-elismetrep-a-novel-approach-for-treating-migraine-presented-at-the-american-academy-of-neurology-annual-meeting-44ecb17d6e0b49c982a61d40c5a8f450
Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the...
Apr 22, 2026 - NEW YORK--(BUSINESS WIRE)--Apr 22, 2026-- Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease...
a noveltreating migrainephase2bstudy